DGAP-News: 4SC Awarded First Place and International Platinum Award for its 2009 Annual Report in the Biotech Category
(firmenpresse) - 4SC AG / Miscellaneous
15.07.2010 07:30
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg-Martinsried, Germany - 15 July, 2010 - 4SC AG (Frankfurt, Prime
Standard: VSC) a drug discovery and development company focused on
autoimmune and cancer indications, won first place and the platinum award,
the highest level award, from the League of American Communications
Professionals (LACP) for its annual report 2009 in the biotech category.
The jury of the LACP, based in San Diego, USA, appraised over 4,000
international annual reports this year from over 29 countries. In addition
to evaluating the transparency and information content of various sections,
the creativity and design were also assessed. 4SC's annual report reached
75th place overall amongst the 4,000 submitted, international annual
reports.
Ulrich Dauer, Chief Development Officer of 4SC commented, 'We are very
happy that our annual report 2009 has received international recognition.
The positive response shows that we are on the right track with our
approach of providing transparent and clear facts to our shareholders, but
also by highlighting the people who stand behind 4SC and enable the
company's progress.'
For further information please contact:
4SC AG
Yvonne Alexander
Investor Relations&Public Relations
Tel: +49 (0) 89 70 07 63 66
yvonne.alexander(at)4sc.com
The Trout Group (USA)
Chad Rubin
Tel: +1 646 378 2947
crubin(at)troutgroup.com
Notes to Editor
About 4SC
4SC AG (ISIN DE0005753818) is a drug discovery and development company
focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a
small molecule, is currently in a Phase IIb study in rheumatoid arthritis
and a Phase IIa exploratory study in inflammatory bowel disease. The
company's lead oncology compound, resminostat (4SC-201), a pan histone
deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular
carcinoma and Hodgkin's lymphoma. Two further oncology compounds, 4SC-203
and 4SC-205 are in Phase I studies. 4SC develops drug candidates until
proof-of-concept in order to generate value creating partnerships with the
pharmaceutical industry in return for advance and milestone payments as
well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.
For further information please visit www.4sc.com.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
15.07.2010 07:30 Ad hoc announcement, Financial News and Press Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
Datum: 15.07.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 23920
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 256 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: 4SC Awarded First Place and International Platinum Award for its 2009 Annual Report in the Biotech Category"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
